Akorn Heads Into Ch. 11 For Sale With More Than $1B In Debt
Specialty pharmaceutical business Akorn Inc. predictably limped into Delaware Bankruptcy Court late Wednesday with Chapter 11 plans for a more than $1 billion all-asset sale, trailed by troubles that include a...To view the full article, register now.
Already a subscriber? Click here to view full article